Literature DB >> 8820920

Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin.

K Nagasawa1, T Natazuka, M Nomiyama, N Ohnishi, T Yokoyama.   

Abstract

We examined the transport mechanisms of daunorubicin (DNR) and doxorubicin (ADR) in HL60 and HL60/THP cells which were the non-P-glycoprotein-mediated resistant clone of the parent HL60 cells and showed a low degree of resistance, and compared them with those of pirarubicin (THP). In both lines, it appeared that the uptakes of DNR and ADR were time-, temperature- and concentration-dependent and energy independent, and the transport of DNR consisted of saturable and nonsaturable components. They were pumped out from the cells time-, temperature- and energy-dependently. There were no differences in the accumulation amount of either DNR or ADR between HL60 and HL60/THP cells. Comparing the transport of DNR or ADR with that of THP, the uptake amounts of DNR and THP were approximately equal, and were greater than that of ADR in both types of cell. In cis-inhibition experiments, DNR inhibited the THP uptake noncompetitively in the parent and resistant cells, in contradiction of the previously reported result in which ADR showed competitive inhibition (Nagasawa, K. et al., Cancer Chemother. Pharmacol., in press). The THP accumulation appeared to be increased by preload of DNR and ADR, indicating a counter transport. Thus, DNR and ADR as well as THP might be incorporated via a common carrier-mediated transport system, but DNR uptake in part appeared to follow a nonsaturable transport, and its binding site in the carrier might differ from that of THP and ADR in both HL60 and HL60/THP cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8820920     DOI: 10.1248/bpb.19.100

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

1.  Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

2.  Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs.

Authors:  K Nagasawa; N Ohnishi; T Yokoyama
Journal:  Jpn J Cancer Res       Date:  1997-08

3.  Contribution of the nucleoside transport system to doxorubicin transport in HL60 cells but not in mononuclear cells.

Authors:  K Nagasawa; T Fumihara; N Ohnishi; T Yokoyama
Journal:  Jpn J Cancer Res       Date:  1999-07

4.  Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin.

Authors:  T Sugiyama; Y Sadzuka; K Nagasawa; N Ohnishi; T Yokoyama; T Sonobe
Journal:  Jpn J Cancer Res       Date:  1999-07

5.  A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer.

Authors:  Matthew T McKenna; Jared A Weis; Stephanie L Barnes; Darren R Tyson; Michael I Miga; Vito Quaranta; Thomas E Yankeelov
Journal:  Sci Rep       Date:  2017-07-18       Impact factor: 4.379

6.  Possibility of contribution of nucleoside transport systems to pirarubicin uptake by HL60 cells but not mononuclear cells.

Authors:  K Nagasawa; N Ohnishi; T Yokoyama
Journal:  Jpn J Cancer Res       Date:  1998-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.